EE04001B1 - Peptiidne farmatseutiline kompositsioon - Google Patents

Peptiidne farmatseutiline kompositsioon

Info

Publication number
EE04001B1
EE04001B1 EEP199900545A EEP9900545A EE04001B1 EE 04001 B1 EE04001 B1 EE 04001B1 EE P199900545 A EEP199900545 A EE P199900545A EE P9900545 A EEP9900545 A EE P9900545A EE 04001 B1 EE04001 B1 EE 04001B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical composition
peptide pharmaceutical
peptide
composition
pharmaceutical
Prior art date
Application number
EEP199900545A
Other languages
English (en)
Inventor
Richardson Peter
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97108593A external-priority patent/EP0880968A1/en
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE9900545A publication Critical patent/EE9900545A/et
Publication of EE04001B1 publication Critical patent/EE04001B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EEP199900545A 1997-05-28 1998-05-26 Peptiidne farmatseutiline kompositsioon EE04001B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97108593A EP0880968A1 (en) 1997-05-28 1997-05-28 Pharmaceutical compositions of peptides having low solubility in physiological medium
EP97121246A EP0880969A1 (en) 1997-05-28 1997-12-03 Pharmaceutical compositions of peptides having low solubility in physiological medium
PCT/EP1998/003079 WO1998053844A1 (en) 1997-05-28 1998-05-26 Pharmaceutical compostions of peptides having low solubility in physiological medium

Publications (2)

Publication Number Publication Date
EE9900545A EE9900545A (et) 2000-06-15
EE04001B1 true EE04001B1 (et) 2003-04-15

Family

ID=26145485

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900545A EE04001B1 (et) 1997-05-28 1998-05-26 Peptiidne farmatseutiline kompositsioon

Country Status (26)

Country Link
US (1) US6331520B1 (et)
EP (2) EP0880969A1 (et)
JP (1) JP2002502384A (et)
KR (1) KR100552546B1 (et)
CN (1) CN1159062C (et)
AR (1) AR012868A1 (et)
AT (1) ATE252909T1 (et)
AU (1) AU743152B2 (et)
BG (1) BG64668B1 (et)
BR (1) BR9809708A (et)
CA (1) CA2291765A1 (et)
CZ (1) CZ298825B6 (et)
DE (1) DE69819322T2 (et)
DK (1) DK0984788T3 (et)
EA (1) EA002227B1 (et)
EE (1) EE04001B1 (et)
ES (1) ES2210772T3 (et)
IL (2) IL133176A0 (et)
NO (1) NO323697B1 (et)
NZ (1) NZ500777A (et)
PL (1) PL192647B1 (et)
PT (1) PT984788E (et)
SI (1) SI0984788T1 (et)
SK (1) SK284640B6 (et)
TR (1) TR199902865T2 (et)
WO (1) WO1998053844A1 (et)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343186B2 (en) 2004-04-06 2013-01-01 Arthrex, Inc. Fully threaded suture anchor with transverse anchor pin
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
US20040229334A1 (en) * 2003-05-15 2004-11-18 Mendoza Christine B. Process for manufacture of nematode-extracted anticoagulant protein (NAP)
US20080249017A1 (en) * 2007-04-04 2008-10-09 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
US9018177B2 (en) 2012-10-12 2015-04-28 L'oreal S.A. Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C
US9107853B2 (en) 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
JP6295261B2 (ja) * 2012-10-12 2018-03-14 ロレアル 少なくとも一種のヒドロトロープ及び少なくとも一種の活性化合物を含む化粧品組成物
US9023826B2 (en) 2012-10-12 2015-05-05 L'oreal S.A. Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use
US9072919B2 (en) 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
BR112018016774A2 (pt) 2016-02-16 2018-12-26 Strongbridge Ireland Limited veldoreotídeo com fraca solubilidade em condições fisiológicas para o uso no tratamento da acromegalia, câncer em acromegalia, tumores que expressam sst-r5, diabetes tipo 2, hiperglicemia e tumores relacionados a hormônio
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
US20200093884A1 (en) 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
CA2070814A1 (en) * 1989-12-21 1991-06-22 Klavs H. Jorgensen Insulin preparations containing nicotinic acid or nicotinamide
CA2070061C (en) * 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
DE69231536T2 (de) * 1991-08-26 2001-06-13 Abbott Laboratories, Abbott Park Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
JP2944419B2 (ja) * 1993-05-10 1999-09-06 ノバルティス アクチエンゲゼルシャフト 持続性遊離組成物中の薬理学的活性成分の安定
TW280770B (et) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
AU3562195A (en) * 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제

Also Published As

Publication number Publication date
EP0880969A1 (en) 1998-12-02
BR9809708A (pt) 2000-07-11
NO323697B1 (no) 2007-06-25
SK159799A3 (en) 2000-07-11
EE9900545A (et) 2000-06-15
PL336982A1 (en) 2000-07-31
KR20010012253A (ko) 2001-02-15
WO1998053844A1 (en) 1998-12-03
NZ500777A (en) 2001-09-28
EP0984788B1 (en) 2003-10-29
DK0984788T3 (da) 2004-03-08
HK1029928A1 (en) 2001-04-20
CA2291765A1 (en) 1998-12-03
BG103884A (en) 2000-07-31
IL133176A0 (en) 2001-03-19
DE69819322D1 (de) 2003-12-04
IL133176A (en) 2006-08-01
AU743152B2 (en) 2002-01-17
AR012868A1 (es) 2000-11-22
US6331520B1 (en) 2001-12-18
CN1159062C (zh) 2004-07-28
CN1263469A (zh) 2000-08-16
CZ423199A3 (cs) 2000-05-17
PT984788E (pt) 2004-01-30
AU8106298A (en) 1998-12-30
EA199901089A1 (ru) 2000-06-26
KR100552546B1 (ko) 2006-02-14
ES2210772T3 (es) 2004-07-01
NO995763L (no) 1999-11-24
EP0984788A1 (en) 2000-03-15
SK284640B6 (sk) 2005-08-04
PL192647B1 (pl) 2006-11-30
CZ298825B6 (cs) 2008-02-20
ATE252909T1 (de) 2003-11-15
SI0984788T1 (en) 2004-02-29
EA002227B1 (ru) 2002-02-28
DE69819322T2 (de) 2004-07-29
BG64668B1 (bg) 2005-11-30
TR199902865T2 (xx) 2000-05-22
JP2002502384A (ja) 2002-01-22
NO995763D0 (no) 1999-11-24

Similar Documents

Publication Publication Date Title
EE04294B1 (et) Farmatseutiline kompositsioon piperidinoalkanooldekongestandi kombineerimiseks
EE04440B1 (et) Kaparetseptori opioidpeptiidid ja farmatseutilinekompositsioon
DK0920302T4 (da) Farmaceutisk aerosolsammensætning
ID24654A (id) Formulasi farmasi omeprazola
NO980546D0 (no) Farmasöytiske midler
EE9900545A (et) Farmatseutiline kompositsioon
GB9716244D0 (en) Pharmaceutical compounds
ID29294A (id) Komposisi farmasi
ID18698A (id) Komposisi farmasi
ID25857A (id) Komposisi farmasi
ITMI962628A0 (it) Composizione farmaceutica
ID23531A (id) Komposisi farmasi
EP1032586A4 (en) PEPTIDES CONTAINING HYPUSINE
BR1100755A (pt) composição farmacêutica
DK1017798T3 (da) Lunasinpeptider
NO20000976D0 (no) Peptider
ID21180A (id) Senyawa-senyawa farmasi
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
SE9804128D0 (sv) A new pharmaceutical composition
DK1037604T3 (da) Farmaceutiske aerosolsammensætninger
FI3163U1 (fi) Lääkesäiliö
SE9601854D0 (sv) Farmaceutisk komposition
ID17133A (id) Komposisi farmasi
SE9604299D0 (sv) Pharmaceutical composition
IT1291652B1 (it) Composizioni farmaceutiche a copertura terapeutica programmata

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20071231

MM4A Lapsed by not paying the annual fees

Effective date: 20080526